Also in recruitment is a phase IIa study of DC vaccines against HER2/HER3 and pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer (https://classic.clinicaltrials.gov/ct2/show/NCT04348747). This evidence concerns the gene ERBB2 and breast carcinoma.